Kwality Pharmaceuticals Ltd (BSE: 539997) is an Amritsar, Punjab-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,091 Cr, it ranks #926 by market cap among the 6,197 Indian listed companies on FinBizNet, and #31 of 86 in Medicinal Chemicals and Botanical Products. At ₹3,842.20 (as of 16 Nov 2026), the share price is 8.8% below its 52-week high of ₹4,211.00 and 22.5% above its 52-week low of ₹3,137.00.
| Current Price | ₹3,842.20 |
|---|---|
| Market Cap | ₹4,091 Cr |
| BSE Code | 539997 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 60.7 |
| Return on Equity | 22.74% |
| Return on Assets | 12.08% |
| 52-Week Range | ₹3,137.00 – ₹4,211.00 |
| 3-Month Price Change | +66.4% |
| Beta (1Y) | 1.06 |
| Dividend Yield | 0.00% |
| Headquarters | Amritsar, Punjab |
| Website | www.kwalitypharma.com |
| Revenue | ₹162 Cr |
|---|---|
| Net Profit | ₹26 Cr |
| Net Margin | 15.8% |
| EPS (Basic) | ₹24.70 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Kwality Pharmaceuticals Ltd reported revenue of ₹162 Cr in Q1 FY27, up 45.6% from ₹111 Cr in Q1 FY26 and up 3.5% from ₹157 Cr in Q4 FY26. It posted a net profit of ₹26 Cr for the quarter, against a net profit of ₹12 Cr in Q1 FY26 (up 114.8%). Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹111 Cr (Q2 FY26) to ₹162 Cr (Q1 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹162 Cr | ₹26 Cr | 15.8% |
| Q4 FY26 | ₹157 Cr | ₹25 Cr | 16.1% |
| Q3 FY26 | ₹123 Cr | ₹16 Cr | 13.0% |
| Q2 FY26 | ₹111 Cr | ₹14 Cr | 12.7% |
| Q1 FY26 | ₹111 Cr | ₹12 Cr | 10.7% |
| Q4 FY25 | ₹116 Cr | ₹15 Cr | 12.5% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 61.90% of Kwality Pharmaceuticals Ltd's shares as of Mar 2026, unchanged from Feb 2026. Delivery averaged 43.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including liquid orals, powder for oral suspension, dry syrups, tablets, capsules, sterile powder for injections, small volume parentals (liquid and lyophilized), pre filled syringes, ointments and creams, ophthalmic preparations, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized products, syrups, daunorubicin, and various other categories such as general, beta-lactam, cephalosporins, cytotoxic (oncology), and biological. It also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.
1. Pharmaceuticals-This segment engages in manufacturing of a range of finished pharmaceutical formulations in a dosage forms, such as tablets, capsules, syrup, dry syrup, injections etc.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Kwality Pharmaceuticals Ltd | ₹4,091 Cr | 60.7 | 22.74% | ₹162 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Kwality Pharmaceuticals Ltd is trading at ₹3,842.20, with a market capitalisation of ₹4,091 Cr.
Kwality Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kwality Pharmaceuticals Ltd has a P/E of 60.7 and a return on equity of 22.74%.
Kwality Pharmaceuticals Ltd is listed on the BSE under the scrip code 539997.
In Q1 FY27, Kwality Pharmaceuticals Ltd reported revenue of ₹162 Cr and net profit of ₹26 Cr, with basic EPS of ₹24.7 (standalone, parsed from the company's exchange filing).
Kwality Pharmaceuticals Ltd reported revenue of ₹162 Cr in Q1 FY27, up 45.6% from ₹111 Cr in Q1 FY26 and up 3.5% from ₹157 Cr in Q4 FY26.
Promoters held 61.90% of Kwality Pharmaceuticals Ltd's shares as of Mar 2026, unchanged from Feb 2026.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.